CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 105 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q3 2019. The put-call ratio across all filers is 1.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $108,000 | +285.7% | 59,269 | +307.0% | 0.00% | – |
| Q1 2021 | $28,000 | +33.3% | 14,562 | -16.1% | 0.00% | – |
| Q4 2020 | $21,000 | -98.4% | 17,349 | -97.6% | 0.00% | -100.0% |
| Q3 2020 | $1,324,000 | +28.7% | 735,920 | +500.2% | 0.00% | 0.0% |
| Q2 2020 | $1,029,000 | +208.1% | 122,608 | +92.4% | 0.00% | – |
| Q1 2020 | $334,000 | +413.8% | 63,739 | +373.9% | 0.00% | – |
| Q3 2019 | $65,000 | -40.4% | 13,449 | -14.4% | 0.00% | – |
| Q2 2019 | $109,000 | +10.1% | 15,720 | +11.6% | 0.00% | – |
| Q1 2019 | $99,000 | +25.3% | 14,092 | +33.9% | 0.00% | – |
| Q3 2018 | $79,000 | +8.2% | 10,525 | -27.8% | 0.00% | – |
| Q2 2018 | $73,000 | -53.2% | 14,582 | -42.7% | 0.00% | – |
| Q1 2018 | $156,000 | -72.2% | 25,460 | -67.8% | 0.00% | -100.0% |
| Q4 2017 | $562,000 | +171.5% | 79,075 | +172.7% | 0.00% | – |
| Q3 2017 | $207,000 | +31.8% | 28,993 | +52.6% | 0.00% | – |
| Q1 2017 | $157,000 | – | 18,998 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 5,045,870 | $42,335,000 | 24.44% |
| MANGROVE PARTNERS IM, LLC | 552,200 | $4,633,000 | 1.13% |
| ETF MANAGERS GROUP, LLC | 3,707,912 | $31,109,000 | 1.10% |
| Ikarian Capital, LLC | 1,350,000 | $11,327,000 | 0.90% |
| GENERAL AMERICAN INVESTORS CO INC | 712,400 | $5,977,000 | 0.76% |
| AdvisorShares Investments LLC | 189,814 | $1,593,000 | 0.68% |
| Ikarian Capital, LLC | 1,000,000 | $8,390,000 | 0.67% |
| Granite Point Capital Management, L.P. | 1,123,600 | $9,427,000 | 0.48% |
| Carmignac Gestion | 3,773,440 | $31,659,000 | 0.44% |
| Omnia Family Wealth, LLC | 32,356 | $271,467,000 | 0.27% |